HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kirsh, M. M. Articles by Sloan, H. Search for Related Content PubMed PubMed Citation Articles by Kirsh, M. M. Articles by Sloan, H.

The Annals of Thoracic Surgery, Vol 34, 34-39, Copyright © 1982 by The Society of Thoracic Surgeons

ARTICLES

Carcinoma of the lung in women

MM Kirsh, J Tashian and H Sloan

The 5-year survival of 293 men and of 78 women undergoing pulmonary resection and mediastinal lymph node dissection is compared. These patients were broken into two age groups: Group 1, 40 through 49 years of age, and Group 2, 50 years of age and older. They were subdivided further according to clinical stage, cell type, and sex. Of the 25 men in Group 1, 15 (60%) survived 5 years, while 98 (37%) of the 268 men in Group 2 survived 5 years. Among the 31 women in Group 1, 5 (16%) survived for 5 years, while 15 (32%) of the 47 women in Group 2 survived for that length of time. The survival among women in the younger age group was significantly lower than for both groups of women in the older age group (p = 0.0335) and men in the younger age group (p = 0.0033). This is believed to be due to the higher incidence of both Stage III disease and adenocarcinoma in the younger women. Twenty-two of the younger women (71%) were classified Stage III compared with 14 (30%) of the older women. Fourteen younger men (56%) had reached Stage III, and 101 older men (38%) were classified as Stage III. These data suggest that sex is an important factor in determining survival because there appears to be a relationship between it and the stage of the disease, and cell type. Overall, women had a poorer 5-year survival than men. Younger women have a strikingly lower survival than any other group, which is explained by their higher incidence of both Stage III classification and adenocarcinoma.

This article has been cited by other articles:

				C.-T. Wu, Y.-L. Chang, J.-Y. Shih, and Y.-C. Lee The significance of estrogen receptor {beta} in 301 surgically treated non-small cell lung cancers J. Thorac. Cardiovasc. Surg., October 1, 2005; 130(4): 979 - 986. [Abstract] [Full Text] [PDF]

				G. E. Goodman, M. D. Thornquist, J. Balmes, M. R. Cullen, F. L. Meyskens Jr., G. S. Omenn, B. Valanis, and J. H. Williams Jr. The Beta-Carotene and Retinol Efficacy Trial: Incidence of Lung Cancer and Cardiovascular Disease Mortality During 6-Year Follow-up After Stopping {beta}-Carotene and Retinol Supplements J Natl Cancer Inst, December 1, 2004; 96(23): 1743 - 1750. [Abstract] [Full Text] [PDF]

				D. J. Barnes The Changing Face of Lung Cancer Chest, December 1, 2004; 126(6): 1718 - 1721. [Full Text] [PDF]

				E. Radzikowska, P. Glaz, and K. Roszkowski Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases Ann. Onc., July 1, 2002; 13(7): 1087 - 1093. [Abstract] [Full Text] [PDF]

				H. Minami, M. Yoshimura, Y. Miyamoto, H. Matsuoka, and N. Tsubota Lung Cancer in Women : Sex-Associated Differences in Survival of Patients Undergoing Resection for Lung Cancer Chest, December 1, 2000; 118(6): 1603 - 1609. [Abstract] [Full Text] [PDF]